Insilico Medicine Initiates First-in-Human Study of AI-Discovered Drug (ISM001-055); Novel Drug, Intended to Treat Idiopathic Pulmonary Fibrosis (IPF), Discovered Using Insilico’s Proprietary End-to-End AI Platform

On November 30, 2021, Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company headquartered in New York City and Hong Kong, announced that the first healthy volunteer has been dosed in a first-in-human microdose trial of ISM001-055. The achievement is described in a lecture by Dr. Michael Levitt, who shared the 2013 Nobel Prize in Chemistry, in the context of the history of AI-powered drug discovery and a brief video explainer.